ND-336 is a selective inhibitor of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-14, with K_is of 85, 150, and 120 nM, respectively. ND-336 accelerates diabetic wound healing in mice by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound.

ND-336 accelerates diabetic wound healing by decreasing inflammation and by enhancing angiogenesis and re-epithelialization of the wound, thus reversing the pathological condition.
ND-336 (0.05-0.01 mg; topical application; daily for 14 day) accelerates diabetic wound healing.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

ND-336 accelerates diabetic wound healing by decreasing inflammation and by enhancing angiogenesis and re-epithelialization of the wound, thus reversing the pathological condition.
ND-336 (0.05-0.01 mg; topical application; daily for 14 day) accelerates diabetic wound healing.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Gao M, et al. Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy. Proc Natl Acad Sci U S A. 2015;112(49):15226-15231.  [Content Brief]

  . Nguyen TT, et al. Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J Med Chem. 2018;61(19):8  [Content Brief]